human | Q5 |
P3835 | Mendeley person ID | omar-niss |
P496 | ORCID iD | 0000-0003-4157-4644 |
P1153 | Scopus author ID | 56333974400 |
P734 | family name | Niss | Q10601289 |
Niss | Q10601289 | ||
Niss | Q10601289 | ||
P735 | given name | Omar | Q4475314 |
Omar | Q4475314 | ||
P106 | occupation | researcher | Q1650915 |
P21 | sex or gender | male | Q6581097 |
Q39269713 | A reappraisal of the mechanisms underlying the cardiac complications of sickle cell anemia |
Q92216646 | Abnormal submaximal cardiopulmonary exercise parameters predict impaired peak exercise performance in sickle cell anemia patients |
Q52758738 | Applications of cardiac magnetic resonance imaging in sickle cell disease. |
Q51000056 | Association between diffuse myocardial fibrosis and diastolic dysfunction in sickle cell anemia. |
Q42365049 | Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia |
Q36677950 | Cardiomyopathy With Restrictive Physiology in Sickle Cell Disease |
Q91316246 | Corrigendum: The Spectrum of SPTA1-Associated Hereditary Spherocytosis |
Q88751362 | Diastolic dysfunction is associated with exercise impairment in patients with sickle cell anemia |
Q41634665 | Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis |
Q35130847 | IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome |
Q48315547 | Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial. |
Q91576755 | Lymphopenia in adults after the Fontan operation: prevalence and associations |
Q92997938 | Non-transfusion-dependent β-Thalassemia Because of a Single β-Thalassemia Mutation and Coinherited α-Globin Gene Triplication: Need for Increased Awareness to Prevent Incorrect and Delayed Diagnosis |
Q91913655 | Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study |
Q92660359 | RGL2 Deficiency Impairs Human Erythropoiesis By Altering Terminal Erythroid Differentiation and Apoptosis |
Q92151414 | Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia |
Q95526094 | The Authors Reply |
Q92105504 | The Spectrum of SPTA1-Associated Hereditary Spherocytosis |
Search more.